{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:42Z","timestamp":1792802142073,"version":"4.5.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/cid\/cix505","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T19:13:13Z","timestamp":1495825993000},"page":"1085-1093","source":"Crossref","is-referenced-by-count":85,"title":["High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection"],"prefix":"10.1093","volume":"65","author":[{"given":"Amy L","family":"Sandul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nwabunie","family":"Nwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Mike","family":"Holcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N","family":"Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asween","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Mukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth N","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jereb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundari","family":"Mase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Chorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Bamrah-Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"key\n\t\t\t\t20170914213532_CIT0001","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20170914213532_CIT0002","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170914213532_CIT0003","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170914213532_CIT0004","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"TB Trials Consortium PREVENT TB Study Team","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170914213532_CIT0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170914213532_CIT0006","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170914213532_CIT0007","article-title":"Adverse drug reactions (adverse drug effects)","volume-title":"Merck manual: professional version","year":"2016"},{"key":"key\n\t\t\t\t20170914213532_CIT0008","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/dyr218","article-title":"Recommendations for presenting analyses of effect modification and interaction","volume":"41","year":"2012","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20170914213532_CIT0009","author":"Sanofi US","year":"2014"},{"key":"key\n\t\t\t\t20170914213532_CIT0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170914213532_CIT0011","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium","year":"2015","journal-title":"JAMA Pediatr"},{"key":"key\n\t\t\t\t20170914213532_CIT0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1037\/0278-6133.26.1.68","article-title":"Latent variable assessment of outcomes in a nurse-managed intervention to increase latent tuberculosis treatment completion in homeless adults","volume":"26","year":"2007","journal-title":"Health Psychol"},{"key":"key\n\t\t\t\t20170914213532_CIT0013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3200\/JACH.57.5.553-556","article-title":"Isoniazid completion rates for latent tuberculosis infection among college students managed by a community pharmacist","volume":"57","year":"2009","journal-title":"J Am Coll Health"},{"key":"key\n\t\t\t\t20170914213532_CIT0014","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1473-3099(13)70015-X","article-title":"Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/7\/1085\/19918728\/cix505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T01:35:42Z","timestamp":1505439342000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/65\/7\/1085\/3858897\/High-Rate-of-Treatment-Completion-in-Program"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,5,30]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix505","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]}}}